MDS Reports Second Quarter 2009 Financi...(ical Technologies reported $13 million i...),Health

Date:6/11/2009

ical Technologies reported $13 million in adjusted EBITDA, compared with $17 million in the corresponding quarter last year. Excluding $5 million of unfavorable impact from foreign exchange, primarily as a result of hedge positions established in 2008, adjusted EBITDA increased $1 million or 4%, driven by restructuring and productivity savings, which were largely offset by pricing and lower volumes. For the quarter, MDS Analytical Technologies reported $87 million in revenue, down 26% from $118 million in the prior year. The effect of foreign exchange reduced reported revenue by $11 million, or 9% year-over-year. Including the impact of foreign exchange, total end-user revenue decreased 13%, with an 11% decline in mass spectrometry end-user revenue. Soft end-user demand in pharmaceutical markets for instruments was the primary driver for the year-over-year decline in volumes across all product lines. The Company continues to see growth in applied markets, services and new products - particularly the recently launched 5500 series of mass spectrometers, which are being well received by customers.

In the second quarter, MDS Analytical Technologies continued to introduce innovative technologies and products. The Company and its joint venture partner, Applied Biosystems (a division of Life Technologies Corporation) launched the AB SCIEX TOF/TOF(TM) 5800 system - the fastest, most sensitive MALDI-based mass spectrometer ever built. This system is already commercially available and will help researchers advance the discovery of biomarkers. MDS Analytical Technologies and Applied Biosystems also introduced a new suite of iMethod tests that simplify the use of mass spectrometry for food and water quality testing, forensic toxicology and clinical research, and MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 image acquisition and analysis software, which are designed to accelerate the throughput of high content screening and expand toxicity applications.

'/>"/>

SOURCE MDS Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine news :

1. Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results
2. Chindex International, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
3. Spencers Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High
4. Streamline Health(R) Solutions Reports First Quarter Results
5. Health Department Reports Pennsylvanias First Death Due to 2009 Novel Influenza A/H1N1 Virus
6. Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results
7. Cantel Medical Reports a 109% Increase in Net Income - EPS of $0.25 vs. $0.12 for Quarter Ended April 30, 2009
8. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Age Affects Her Chances of Successful Pregnancy from Egg Donation
9. Social Security Disability Benefits Awarded Disparately Across the US Reports www.social-security-lawyers.net
10. Americans Want Insurers and Physicians to Use Technology to Coach Them to Healthier Habits, Reports New National Survey From Microsoft
11. LCA-Vision Reports on Annual Meeting of Stockholders